drugset
drugset / Trial / NCT07123441

A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer

NCT07123441 ↗

Phase 2 Not yet recruiting 300 enrolled Sanjun Cai
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label clinical trial designed to evaluate the efficacy and safety of irinotecan liposome (II), 5-FU/LV in combination with bevacizumab for the treatment of advanced colorectal cancer.

Timeline

Start
2025-09-01
Primary completion
2027-09-01
Completion
2028-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 5 mg/kg Intravenous
Subject Irinotecan Small molecule 60 mg/m2 Intravenous
Subject LV Unknown 400 mg/m2 Intravenous
Subject fluorouracil Small molecule 400 mg/m2 Intravenous
Subject fluorouracil Small molecule 1200 mg/m2 Intravenous

Indications

colorectal cancer